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Abstract: Innate responses provide the first line of defense against viral infections, including the
influenza virus at mucosal surfaces. Communication and interaction between different host cells at
the early stage of viral infections determine the quality and magnitude of immune responses against
the invading virus. The release of membrane-encapsulated extracellular vesicles (EVs), from host
cells, is defined as a refined system of cell-to-cell communication. EVs contain a diverse array of
biomolecules, including microRNAs (miRNAs). We hypothesized that the activation of the tracheal
cells with different stimuli impacts the cellular and EV miRNA profiles. Chicken tracheal rings were
stimulated with polyI:C and LPS from Escherichia coli 026:B6 or infected with low pathogenic avian
influenza virus H4N6. Subsequently, miRNAs were isolated from chicken tracheal cells or from
EVs released from chicken tracheal cells. Differentially expressed (DE) miRNAs were identified
in treated groups when compared to the control group. Our results demonstrated that there were
67 up-regulated miRNAs, 157 down-regulated miRNAs across all cellular and EV samples. In the next
step, several genes or pathways targeted by DE miRNAs were predicted. Overall, this study presented
a global miRNA expression profile in chicken tracheas in response to avian influenza viruses (AIV)
and toll-like receptor (TLR) ligands. The results presented predicted the possible roles of some DE
miRNAs in the induction of antiviral responses. The DE candidate miRNAs, including miR-146a,
miR-146b, miR-205a, miR-205b and miR-449, can be investigated further for functional validation
studies and to be used as novel prophylactic and therapeutic targets in tailoring or enhancing antiviral
responses against AIV.
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1. Introduction
Avian influenza viruses (AIVs) are negative-sense single-stranded RNA viruses belonging to the
Orthomyxoviridae family. AIVs cause transmissible viral infections affecting several species of poultry,
such as chickens and turkeys, as well as wildfowl. These viruses are classified into two pathotypes that
are based on their pathogenesis in poultry: low pathogenic and highly pathogenic viruses. Additionally,
AIVs cause respiratory infections, declines in production, and elevated mortality rates.
During the early stages of the infection, innate responses provide the first line of defense against
the infections at mucosal surfaces by aiming to block the entry of the virus and viral replication.
However, when the virus crosses the primary barrier, the airway epithelial cells become the target of
the virus. Host cells detect the presence of viral components and, subsequently, antiviral responses will
be induced. Previously, we confirmed the induction of antiviral responses in the chicken respiratory
system [1–3]. In the absence of appropriate antiviral responses against the virus, viral replication in the
host cells leads to pathological changes, such as necrosis of tracheal epithelial cells and the infiltration
of inflammatory cells into the site of infection.
Furthermore, innate responses deliver information about the virulence, pathogenicity, and presence
of pathogens within the host cells. In addition, immune responses influence the communication
and coordination between the different host cells [4]. The induction of innate antiviral responses,
the production of antiviral factors, and the regulation of viral activity are highly regulated processes
that largely depend on intracellular communication mechanisms, including cell-to-cell contact, secretion
of cytokines and chemokines, as well as the release of extracellular vesicles (EVs) [5]. Exosomes are
membrane-encapsulated EVs measuring approximately 30 to 150 nm in diameter that can act as mediators
of intracellular communication [6,7]. Studies in mammalian species have shown that EVs, including
exosomes, contain a diverse array of biomolecules, including proteins, lipids, messenger RNAs (mRNAs),
and microRNAs (miRNAs) [5]. They can transfer their contents to neighboring cells. In addition,
there is some evidence that EVs and their contents play a role in modulating antiviral responses, but this
phenomenon and the mechanism by which it occurs is poorly characterized in chickens [8–11].
MicroRNAs are conserved, small, non-coding RNA molecules that regulate the gene expression
of complementary mRNA sequences, usually in the 3′ untranslated region (UTR), by base
pairing, resulting in gene silencing through translational repression or target degradation [12,13].
Complete complementarity between a miRNA and its target sequence is rare in animals, but a match of
as little as six base pairs in the seed region of the miRNA (nucleotides 2–8) can be sufficient to induce
the suppression of gene expression [14]. As a result, a given miRNA can have multiple targets affecting
multiple intracellular signaling pathways. MiRNAs have been shown to regulate several biological
processes, such as development, differentiation, organogenesis, growth control, and apoptosis [15].
Extracellular miRNAs, which are packaged in exosomes, microvesicles, or apoptotic bodies, are stable
and can survive in the harsh conditions of the extracellular environment. MiRNAs are also found
intracellularly, but are subjected to more rapid degradation in the extracellular environment [16].
Regardless of their localization, miRNAs play an important role in cell-to-cell communication and the
modulation of intracellular signaling. Furthermore, studies characterizing miRNA profiles revealed
that certain miRNAs are induced upon infection with viruses and can modulate antiviral responses
by targeting intracellular pathways [17–21]. Recent studies in humans have also demonstrated that
cellular miRNAs are capable of regulating translation and replication in RNA viruses by directly
binding to the virus genome [22–27]. In addition, studies in chickens have identified several miRNAs
that are involved in immune responses against avian pathogens, such as avian pathogenic Escherichia
coli (APEC), Newcastle disease virus (NDV), and Marek’s disease virus (MDV) [28–31]. Moreover,
previous studies demonstrated the expression of miRNAs following AIV infections in chickens [32,33].
Despite an increasing understanding of the induction of antiviral responses in chickens, studies
are required in order to determine the mechanisms by which EVs, and EV and cellular miRNAs
influence and regulate antiviral responses. In this study, we aimed to determine the miRNA contents
of EVs released from chicken tracheal cells following AIV infection. Moreover, we were interested in
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identifying whether the type of stimuli or infection can impact the profile of cellular and EV miRNAs.
Therefore, in the current study, we characterized the profile of miRNAs and their potential targets
that are involved in antiviral responses following the infection of chicken tracheal cells with AIV and
stimulation with TLR3 and 4 ligands.
2. Materials and Methods
2.1. Avian Influenza Virus (AIV)
Eleven-day-old specific-pathogen-free (SPF) embryonated chicken (layer chickens, white Leghorn)
eggs (Canadian Food Inspection Agency, Ottawa, ON, Canada) were used to propagate influenza virus
A/Duck/Czech/56 (H4N6), a low pathogenic avian influenza virus (LPAIV) by inoculation through
the allantoic cavity [34]. For the inoculation, the eggs were candled, and then the virus was injected
with 100 µL of stock allantoic fluid containing 0.2 hemagglutinin units (HAU) of the H4N6 virus.
The allantoic fluid was harvested 48 h post-inoculation. The virus titer was determined using end-point
dilution in Madin-Darby Canine Kidney (MDCK) cells (a gracious gift from Dr. Shayan Sharif’s
laboratory at the Ontario Veterinary College, University of Guelph, ON, Canada) and hemagglutinin
assay (HA) [35].
2.2. Toll-Like Receptor (TLR) Ligands
Lipopolysaccharide (LPS) from Escherichia coli 026:B6 (Sigma–Aldrich, Oakville, ON, Canada) and
polyinosinic:polycytidylic acid (polyI:C) (InvivoGen, San Diego, CA, USA) were used in this study.
These ligands were selected, as they were previously shown to induce immune responses in chicken
tracheal cells [2,36].
2.3. Tracheal Organ Culture (TOC)
Tracheal organ culture (TOC) was performed, as previously described [2]. Briefly, tracheas were
aseptically collected from 19-day-old SPF chicken embryos (Canadian Food Inspection Agency, Ottawa,
ON, Canada) and, subsequently, washed twice with warm Hanks’ balanced salt solution (HBSS, Gibco,
Burlington, ON, Canada) in order to remove excess mucus. The connective tissues surrounding the
trachea were removed by thorough dissection. Tracheas were manually dissected into 1 mm rings using
razor blades and then transferred into 24-well cell culture plates containing phenol red-free complete
Medium 199 (Sigma–Aldrich, Oakville, ON, Canada). Complete Medium 199 was supplemented
with 10% EV-depleted and heat-inactivated fetal bovine serum (FBS, Gibco, Burlington, ON, Canada),
25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (Gibco, Burlington, ON,
Canada), 200 U/mL penicillin/80 µg/mL streptomycin (Gibco, Burlington, ON, Canada), and 50 µg/mL
gentamicin (Gibco, Burlington, ON, Canada). To prepare EV-depleted FBS, FBS was heat-inactivated at
56 ◦C for 30 min. and then depleted of EVs by ultracentrifugation. To this end, complete Medium
199 containing 20% FBS were centrifuged overnight (18 h) at 100,000× g at 4 ◦C. The top layer was
collected, and the resulting 20% FBS-depleted medium was then filtered through a 0.2 µm filter and
diluted to the half with complete Medium 199 without FBS to reach 10% of FBS. The rings were then
incubated at room temperature on a low-speed benchtop rocker for 3 h to exclude any possible reaction
and mucus production during the TOC preparation. Following the incubation, the media was replaced
with fresh media. During the experiments, the ciliary activity of the tracheal rings was observed under
a light microscope in order to monitor the condition of TOCs and confirm the cilia activity of TOCs.
2.4. TOC Infection with AIV (H4N6) and Stimulation with TLR Ligands
Stimulation for all treatment groups was done in complete FBS-free Medium 199 as animal sera
contain non-specific inhibitors of influenza viruses [37]. For infection of TOCs with AIV (H4N6),
tracheal rings were infected with 104 pfu/mL. For the stimulation of TOCs with TLR ligands, tracheal
rings were stimulated with either LPS (1 µg/mL) or polyI:C (25 µg/mL) (doses were selected based
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on previous studies in chickens) [2,36,38]. The control groups received complete FBS-free Medium
199. The final volume for each well was 500 µL. After 2 h of stimulation, tracheal rings were washed
twice and incubated at 37 ◦C in fresh complete FBS-free Medium 199. The tracheal rings designated
for cellular miRNA extraction (TOC samples), consisting of six biological replicates (six individual
embryos) per treatment group, were collected 3- and 18-h post-infection or -stimulation and stored at
−80 ◦C in RNAlater (Invitrogen, Burlington, ON, Canada). The tracheal supernatants of the rings that
were designated for EV isolation and subsequent EV miRNA extraction (EV samples) were collected
24-h post-infection or -stimulation. For EV samples, there were three biological replicates (pools of five
individual embryos per replicate) for each treatment group.
2.5. Extracellular Vesicle Isolation
All of the centrifugations and ultracentrifugations were performed at 4◦C. Tracheal supernatants
from EV samples were centrifuged at 300× g for 10 min. to remove cellular debris. Subsequently,
supernatants were recovered and centrifuged at 2000× g for 20 min. Supernatants were again recovered
and ultracentrifuged at 10,000× g for 30 min. (Optima L-100XP, Beckman Coulter, Mississauga, ON,
Canada). Supernatants were recovered and filtered with 0.2 µm filters (VWR, Montreal, QC, Canada).
Supernatants were then ultracentrifuged at 100,000× g for 60 min. (Optima L-100XP, Beckman Coulter,
Mississauga, ON, Canada). Supernatants were discarded and pellets were resuspended in FBS-free
complete Medium 199 and ultracentrifuged at 100,000× g for a final 60 min. (Optima L-100XP, Beckman
Coulter, Mississauga, ON, Canada). The supernatants were discarded, and the pellets were resuspended
in 200 µL of phosphate-buffered saline (PBS, Gibco, Burlington, ON, Canada). Finally, for miRNA
isolation from EV samples, 700 µL of QIAzol reagent (QIAGEN, Toronto, ON, Canada) were added
to samples that were designated for RNA isolation and then stored at −80 ◦C. Samples designated for
Western Blot and transmission electron microscopy analyses were stored at −80 ◦C in PBS.
2.6. Western Blot
Western Blot analysis was performed to confirm biomarkers compatible with EVs. The protein
concentrations of the isolated EVs were determined using Micro BCA Protein Assay Kit according
to manufacturer’s instructions (Thermo Fisher Scientific, Burlington, ON, Canada). EV samples
were lysed with RIPA Lysis Buffer (EMD Millipore, Oakville, ON, Canada) and incubated on ice
for 5 min. The samples were then treated with NuPAGE LDS Sample Buffer (4X) containing 5%
2-mercaptoethanol (Invitrogen, Burlington, ON, Canada) and denatured for 5 min. at 95 ◦C. Equal
amounts of proteins (about 30 µg) were separated by SDS-PAGE using pre-cast Mini-PROTEAN
TGX electrophoresis gels (Bio-Rad, Montreal, QC, Canada). The separated proteins were transferred
onto activated polyvinylidene difluoride (PVDF) membranes (Sigma–Aldrich, Oakville, ON, Canada).
The membranes were washed in Tris-buffered saline with 0.05% Tween 20 (TBS-T), blocked in 5%
skimmed milk TBS-T solution, and then washed again in TBS-T. The membranes were incubated with the
primary antibody overnight at 4 ◦C, followed by the appropriate secondary antibody diluted in TBS-T
for 1h at room temperature. Proteins were detected using Clarity Max enhanced chemiluminescence
(ECL) Substrate (Bio-Rad, Montreal, QC, Canada), according to the manufacturer’s instructions.
The primary antibodies used for western blot were rabbit polyclonal antibody (pAb)
anti-lysosome-associated membrane protein 1 (LAMP1-lysosome marker) (ab24170, Abcam, Cambridge,
MA, USA), rabbit pAb anti-tumor susceptibility gene 101 (TSG101) (ab225877, Abcam, Cambridge,
MA, USA), rat monoclonal antibody (mAb) anti-glucose-regulated protein 94 (GRP94) (ab2791, Abcam,
Cambridge, MA, USA), and mouse mAb conjugated HRP against β-actin (HRP SC-47778, Santa Cruz
Biotechnology, Dallas, TX, USA). The secondary antibodies used for antibodies were goat-anti-rabbit
IgG Fc (HRP) (4041-05, Southern Biotech, Birmingham, AL, USA) and goat pAb to rat IgG (HRP)
(ab97057, Abcam Cambridge, MA, USA).
Vaccines 2020, 8, 438 5 of 31
2.7. Negative Staining and Transmission Electron Microscopy (TEM)
TEM analysis was performed at the Facility for Electron Microscopy Research (FEMR),
McGill University, to confirm and validate the purity of isolated EVs. Briefly, a 1:1 dilution of
frozen EV samples was thawed and fixed with 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer.
The samples were then allowed to equilibrate at room temperature for 30 min. A 200-mesh copper TEM
grid with carbon support film (Agar Scientific Ltd., Stansted, UK) was negatively glow discharged at 25
mA for 30 s (Electron Microscopy Sciences 100 Glow Discharge System, Hatfield, PA, USA) and loaded
with a 5 µL droplet of sample for 3 min. Excess solution was carefully blotted off with Whatman Grade
1 filter paper and the grid was washed twice with a droplet of glycine for 1 and 2 min., respectively.
The grid was then washed three times with a droplet of MilliQ water for 1 min. Finally, for negative
staining, the grid was first floated on a droplet of 2% uranyl acetate (Electron Microscopy Sciences,
Hatfield, PA, USA) to remove excess water and then on a second droplet for 1 min. Excess liquid
was blotted off with Whatman Grade 1 filter paper. The samples were imaged by the FEI Tecnai G2
Spirit 120 kV TEM (Thermo Fisher Scientific, Hillsboro, OR, USA) equipped with a Gatan Ultrascan
4000 CCD camera Model 895 (Gatan, Inc., Warrendale, PA, USA). The micrographs were taken at
appropriate magnifications to record the fine structure of EVs. The proprietary Digital Micrograph
16-bit images (DM3) were converted to unsigned 8-bit TIFF images.
2.8. MiRNA Isolation
Small RNAs were isolated while using the miRNeasy Mini Kit (QIAGEN, Toronto, ON, Canada)
following the Quick-Start protocol of miRNeasy Mini Kit manufacturer’s instructions. Briefly, tracheal
rings from TOC samples (stored in RNAlater) were collected, lysed in 700 µL of QIAzol reagent
(QIAGEN, Toronto, ON, Canada), and homogenized for two minutes using 0.5 mm glass beads (Biospec
Products Inc., Bartlesville, OK, USA) and a tissue homogenizer (MP FastPrep-24 Classic Instrument,
MP Biomedicals, Solon, OH, USA). The isolated EVs from EV samples were likewise lysed in 700 µL of
QIAzol reagent (QIAGEN, Toronto, ON, Canada). The samples were then deproteinized in chloroform
and centrifuged for 15 min. at 12,000× g at 4 ◦C. The upper aqueous portion of the samples was
precipitated in 95% ethanol. The samples were sequentially washed and centrifuged with RWT and
RPE buffers using RNeasy Mini columns in 2 mL collection tubes (QIAGEN, Toronto, ON, Canada).
Finally, the purified RNA was eluted in 27 µL RNase-free water and quality control of RNA was
performed using the RNA ScreenTape Analysis kit (Agilent Technologies, Santa Clara, CA, USA) and
the Agilent 4200 TapeStation Analysis Software A.02.01 SR1 (Agilent Technologies, Santa Clara, CA,
USA), according to the manufacturer’s instruction. The samples were then stored at −80 ◦C.
2.9. Small RNA Library Preparation and Sequencing
MiRNA sequencing was performed at the Research Center of the CHU de Québec-Université
Laval, Quebec, Canada. Twenty-four libraries for TOC samples (pooling of two replicates from each
treatment group) to give three replicates per group and twelve libraries for EV samples to have three
replicates within each group were prepared using the NEBNext Multiplex Small RNA Library Prep Set
for Illumina (New England Biolabs, Ipswich, MA, USA), according to manufacturer’s instructions.
The total RNA from each sample was sequentially ligated to 3′ and 5′ small RNA adapters using
T4 RNA ligase (New England Biolabs, Ipswich, MA, USA). Next, cDNAs were synthesized through
reverse transcription using ProtoScript II Reverse Transcriptase (New England Biolabs, Ipswich, MA,
USA) and amplified by PCR. Clean up and size selection of fragments was made using the Monarch
PCR & DNA Cleanup Kit (5 µg) (New England Biolabs, Ipswich, MA, USA) and 6% polyacrylamide
gel. Finally, the RNA libraries were sequenced (50 bp single-end) on an Illumina HiSeq 2500 platform
(rapid mode) (Illumina, San Diego, CA, USA).
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2.10. MiRNA Expression Analysis
Raw sequencing reads were processed by removing adapters and low-quality sequences using
Trimmomatic, a read trimming tool for Illumina NGS data [39]. We used FastQC, a quality control
tool for high throughput sequencing data, and MultiQC v1.7, a tool that creates a single report for
different metrics and alignment statistics across many samples, in order to assess the quality of the
generated reads [40,41]. We aligned the clean reads obtained from each library to mature miRNAs and
to the reference genome of Gallus gallus in miRBase version 22.1 database to identify known miRNA
expression levels in each group [42]. The MirDeep2 package, which maps reads against a library of
known miRNAs from miRBase, was used for miRNA quantification from the reads, coordinated by a
Nextflow workflow [43,44]. Small RNA sequencing libraries were normalized to counts per million
(CPM) and evaluated for expression. MiRNA differential expression modeling and calculation were
then done using R and R packages edgeR, tidyverse, magrittr and ComplexHeatmap [45–49]. Furthermore,
the identified miRNAs for each treatment group were considered differentially expressed (DE) if their
normalized expression fold changes (FC) relative to the control group was greater than or equal to 1.5-fold
(log2FC ≥ 0.58 or log2FC ≤ −0.58) and if their False Discovery Rate (FDR) was less than 0.05 (FDR < 0.05).
Venn diagram analysis for the DE miRNAs among the different treatment groups was performed using
the online tool http://bioinformatics.pbs.ugent.be/webtools/Venn/. Furthermore, the distribution and
intersection of the DE miRNAs were visualized using the UpSet software (http://vcglab.org/upset) [50].
2.11. In Silico Target Gene Prediction and Pathway Analysis
We downloaded targets of Gallus gallus’ miRNAs from release 7.2 of TargetScan and version 6.0 of
miRDB in order to perform functional enrichment analysis on the targets of DE miRNAs [51,52]. Next,
we excluded targets with a low confidence score (below 99 ‘context++ score percentile’ for TargetScan
and below 95 ‘target prediction score’ for miRDB), resulting in 4987 unique target genes for 982 miRNAs
from TargetScan and 4887 unique target genes for 973 miRNAs from miRDB. Subsequently, we formed
gene sets corresponding to targets of differentially expressed, up-regulated, and down-regulated
miRNAs, according to TargetScan and miRDB (separately). We excluded genes that were targets of
both up-regulated and down-regulated miRNAs in order to calculate the exact number of host target
genes or host target pathways.
We used the KnowEnG analytical platform (https://knoweng.org/analyze) to perform pathway
and gene ontology (GO) enrichment analysis on these gene sets [53,54]. KnowEnG is a computational
system for analysis of ‘omic’ datasets in light of prior knowledge in the form of various biological
networks. We used the KnowEnG’s gene set characterization (GSC) pipeline in the standard mode (no
knowledge network) and its knowledge-guided mode with the STRING co-expression network [55].
The knowledge-guided mode of this pipeline implements DRaWR, a method that utilizes random
walk with restarts (RWR) in order to incorporate gene-level biological networks in the enrichment
analysis to improve identification of important pathways and GO terms [56]. For the GSC pipeline,
we did not use the bootstrapping option, selected Gallus gallus as ‘species’, and used default values for
all other parameters. In addition, we mapped the Gallus gallus genes to Homo sapiens genes and used
them in the same manner in the GSC pipeline with ‘species’ selected as Homo sapiens. The p-values of
the Fisher’s exact test corresponding to the standard mode of GSC pipeline were corrected for multiple
hypotheses (Benjamini–Hochberg method) and FDR < 0.05 was considered to be significant. For the
network-guided mode of GSC pipeline, the results were filtered based on the ‘Difference Score’ and
those with a value larger than 0.5 were considered. The difference score is the normalized difference
between the query probabilities and the baseline probabilities in the RWR algorithm, with the best
score observed as one [56]. Finally, we used GraphPad Prism 8.4.3 for the illustration of the targeted
pathways by the treatment group [57].
In addition, we performed the prediction of candidate miRNAs targeting influenza viral
genes. The genomic sequences for the AIV strain used in this experiment, A/Duck/Czech/56 (H4N6)
(genome accessions: CY130022, CY130023, CY130024, CY130025, CY130026, CY130027, CY130028,
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CY130029), were obtained from the Influenza Virus Resource at the National Center for Biotechnology
Information [58,59]. Two platforms, miRanda and RNAhybrid, were used to scan the eight segments
of the AIV viral genome for potential target sites of the identified DE miRNA. The source code for
miRanda, (written in C and downloaded from http://www.microrna.org/microrna/getDownloads.do)
was used with default parameters for scaling parameter (4.0), strict 5′ seed pairing (off), gap-opening
penalty (−4.0), and gap-extend penalty (−9.0), and adjusted parameters for score, set to greater
than or equal to 160 (sc ≥ 160), and the minimum free energy (mfe), set to less than or equal to
−16 kcal/mol (en ≤ −16 kcal/mol), as previously suggested [60,61]. Identified miRNA target pairs were
confirmed using RNA hybrid (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/submission.html),
which illustrates hybridization based on mfe [62].
3. Results
3.1. Chicken Tracheal Cells Release Extracellular Vesicles
While there is heterogeneity among EV cargo, depending on cell type and origin, the protein
contents of extracellular vesicles and exosomes have been extensively studied [6].
The average protein concentration across all EV samples was 506 µg/mL. Based on the International
Society for Extracellular Vesicles (ISEV)’ recommendation, our results highlighted the presence of
“EV-enriched” markers and the absence of non-exosomal markers in EV samples by Western Blot
analysis [63]. Our results confirmed the presence of lysosomal LAMP1, a type I transmembrane protein,
in both EV and cell lysate samples (Figure 1a). The LAMP1 protein bands identified in both samples
were of slightly different sizes. This was expected, as the antibody detects a band of approximately
90–130 kDa. The variability in molecular weight is observed as a result of different levels of glycosylation
of the target in different cell and tissue types [64]. In addition, endosomal TSG101, a cytosolic protein,
and cytoskeletal β-actin proteins were detected in EV samples (Figure 1a). Moreover, as expected, the EV
samples lacked endoplasmic reticulum protein, GRP94 (Figure 1a) [63]. Finally, EVs were examined for
morphological characteristics by transmission electron microscopy (TEM), which revealed vesicles of
50–150 nm in diameter with morphological characteristics of EVs (Figure 1b).
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3.2. Cellular and EV Treatment Groups Have Distinct miRNAs Expression Profiles
RNA quality control of the extracted RNA determined an average RNA integrity number (RIN) of
6.0 and an average concentration of 406 ng/µL. Following small-RNA sequencing, low-quality reads
were filtered and adaptor sequences were trimmed. A total of 235,810,088 clean reads were obtained
from TOC samples (three libraries per treatment group). A total of 27,298,247 clean reads were obtained
From EV samples (three libraries per treatment group) (Table S1). Across all samples, the distribution of
the small RNA sequencing length was consistent with the known length of mature miRNA, an average
of 22 nucleotides [65]. The fragment lengths were primarily concentrated at 22 nucleotides (Figure S1).
The miRNA expression profiles were evaluated in order to determine the ability of AIV infection,
and LPS and polyI:C stimulation to influence the expression of cellular and EV miRNAs. A total of 692
known mature chicken miRNAs were detected. Following differential expression filtering (FC ≥ 1.5 and
FDR < 0.05) and mean difference plot analysis, 228 DE unique miRNAs were identified (Figures S2–S4).
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LPS and polyI:C. Lists of DE miRNAs for TOC 3 h, TOC 18 h, and EV treatment groups are shown in 
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that pass the FDR threshold), AIV group. (b) The top three DE miRNAs (of three that pass the FDR 
threshold), LPS group. (c) The top two DE miRNAs (of two that pass the FDR threshold), polyI:C 
group. FDR < 0.05. The density of the colors represents the abundance of each miRNA in the scale of 
log2 counts per million (CPM). 
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Figure 4. Heatmap with hierarchical clustering of miRNA distribution of the top cellular DE miRNAs 
(18 h) ranked by adjusted p-value (FDR). (a) The top eight DE miRNAs (of eight that pass the FDR 
threshold) AIV group. (b) The top 20 DE miRNAs (of 65 that pass the FDR threshold), LPS group. (c) 
Fig re diagram showing DE miRNAs in (a) TOC 3 h groups treated with AIV, LPS and polyI:C,
(b) TOC 18 h groups t eated with AIV, LPS and polyI:C and (c) EV groups treated with AIV, LPS
and polyI:C. Lists of DE miRNAs for TOC 3 h, TOC 18 h, and EV treat ent i
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Within the TOC 3 h groups, a total of 18 unique DE miRNAs, of which two miRNAs were found
in more than one group (Figure 3a–c). Our results demonstrated that 11, three, and two miRNAs were
up-regulated, while four miRNAs were down-regulated in the TOC 3 h, AIV group (Tables 1 and 2).
There were two miRNAs, gga-miR-1608 and gga-miR-6705-5p, which were DE in both the TOC 3 h
AIV and TOC 3 h LPS groups (Figure 2a, Table S2). Furthermore, within the TOC 18 h groups, our
results showed a total of 88 unique DE miRNAs, of which six miRNAs were found in more than one
group (Figure 4a–c). In the TOC 18 h groups, three, 32, and two miRNAs were up-regulated, and two,
15, and 40 miRNAs were down-regulated following treatment with AIV, LPS and polyI:C, respectively
(Tables 1 and 2). There were three miRNAs, gga-miR-1451-5p, gga-miR-1563, and gga-miR-12234-5p,
which were DE in both TOC 18 h AIV and TOC 18 h LPS groups and three miRNAs, gga-miR-6569-5p,
gga-miR-12228-3p, and gga-miR-2184a-3p, which were DE in both the TOC 18 h LPS and TOC 18
polyI:C groups (Figure 2b, Table S3).
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Table 1. Up-regulated miRNAs in TOC 3 h and TOC 18 h following treatment with avian influenza
viruses (AIV), lipopolysaccharide (LPS), and polyI:C. Following differential expression filtering (FC≥ 1.5
and FDR < 0.05), 11, three, and two miRNAs were found to be up-regulated in TOC 3 h AIV, LPS,
and polyI:C groups, respectively. For TOC 18 h AIV, LPS, and polyI:C groups, three, 32, and two
miRNAs were found to be up-regulated in each group, respectively.
Treatment Group MiRNA Log2 Fold Change Fold Change
TOC 3 h
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Table 2. Down-regulated miRNAs in TOC 3 h and TOC 18 h following treatment with AIV, LPS and
polyI:C. Following differential expression filtering (FC ≥ 1.5 and FDR < 0.05), four, zero, and zero
miRNAs were found to be down-regulated in TOC 3 h AIV, LPS, and polyI:C groups, respectively.
For TOC 18 h AIV, LPS, and polyI:C groups, 2, 15, and 40 miRNAs were found to be down-regulated in
each group, respectively.
Treatment Group MiRNA Log2 Fold Change Fold Change
TOC 3 h






TOC LPS 3 h
(0 miRNAs) NONE N/A N/A
TOC polyI:C 3 h
(0 miRNAs) NONE N/A N/A
TOC 18 h
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With respect to the EV groups, a total of 145 unique DE miRNAs were identified, in which
59 miRNAs were found in more than one group (Figure 5a–c). Our results exhibited that 21,
five, and 14 miRNAs were up-regulated in AIV, LPS, and polyI:C groups, respectively, while
57, 17, and 90 miRNAs were down-regulated in AIV, LPS, and polyI:C groups, respectively
(Tables 3 and 4). There were 10 miRNAs, gga-miR-107-5p, gga-miR-1784b-5p, gga-miR-449b-5p,
gga-miR-205b, gga-miR-210a-5p, gga-miR-1727, gga-miR-1464, gga-miR-6665-5p, gga-miR-7482-5p,
and gga-miR-12284-3p, which were DE in all EV groups. In addition, there was one miRNA,
gga-miR-383-5p, which was DE in both the EV AIV and EV LPS groups. Furthermore, 34 miRNAs were
DE in both EV AIV and EV polyI:C groups. Moreover, four miRNAs, gga-miR-211, gga-miR-132b-5p,
gga-miR-1597-5p, and gga-miR-12223-3p were DE in both EV LPS and EV polyI:C groups (Figure 2c,
Table S4).
Across all TOC 3 h, TOC 18 h, and EV groups, there were 67 up-regulated miRNAs,
157 down- regulated miRNAs, and four miRNAs, gga-miR12244-5p, gga-miR210a-5p, gga-miR30b-5p,
and gga-miR-383-5p, which were found to be up-regulated in some groups and down-regulated
in others. The miRNA gga-miR12244-5p was up-regulated in the TOC 18 h AIV group and
down-regulated in the EV AIV group and gga-miR210a-5p was up-regulated in the TOC 3 h AIV and
TOC 18 h LPS groups and down-regulated in all three EV groups. The miRNA gga-miR30b-5p was
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up-regulated in the TOC 18 h LPS group and down-regulated in the EV polyI:C group and, finally,
gga-miR-383-5p was up-regulated in the EV AIV and EV polyI:C groups and down-regulated in the
TOC 3 h AIV group (Tables 1–4).
Table 3. Up-regulated miRNAs in EVs following treatment with AIV, LPS, and polyI:C. Following
differential expression filtering (FC ≥ 1.5 and FDR < 0.05), 21, five, and 14 miRNAs were found to be
up-regulated in EV AIV, LPS, and polyI:C groups, respectively.
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Table 4. Down-regulated miRNAs in EVs following treatment with AIV, LPS, and polyI:C. Following
differential expression filtering (FC ≥ 1.5 and FDR < 0.05), 57, 17, and 90 miRNAs were found to be
down-regulated in EV AIV, LPS, and polyI:C groups, respectively.
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3.3. Target Gene Prediction and Functional Annotation Reveals DE miRNAs Target Multiple Pathways 
The miRDB and TargetScan databases were used to predict the possible gene set or pathway 
targets of DE miRNAs to characterize molecular and immunoregulatory functions of DE miRNAs 
presented in the current study. Target genes were predicted based on Homo sapiens (human), Mus 
musculus (mouse), and Gallus gallus (chicken) targets. However, there was limited information on 
Gallus gallus targets; therefore, the results based on the chicken database are provided in the 
Supplementary Materials (Tables S5–S9). The results presented in this study are based on human and 
mice databases. A total of 105, 34, and 151 projected genes and three, four, and 14 projected pathways 
were targeted by 15, three, and two DE cellular miRNAs in 3 h TOC AIV, LPS, and polyI:C groups, 
respectively. Moreover, 25, 578, and 384 projected genes and 17, 14, and 17 projected pathways were 
targeted by five, 47, and 42 DE miRNAs in 18 h TOC AIV, LPS, and polyI:C treatment groups, 
respectively (Tables 5–7). Finally, a total of 487, 147, and 817 genes and 16, 11, and 23 pathways were 
identified as targets for 78, 22, and 104 DE EV miRNAs following AIV, LPS, and polyI:C treatments 
(EV samples), respectively (Tables 5, 8, and 9). The targeted pathways related to immune responses 
and intracellular signaling are illustrated in Figure 6, while a complete list of targeted pathways and 
the respectively responsible miRNAs are provided in Tables 6–9. 
Table 5. Pathway analysis summary. Host target genes for DE miRNAs were predicted using the miRDB human 
and mouse databases. Pathway analysis was then performed using the gene set characterization pipeline by 
KnowEnG. Only hits with scores greater than or equal to 95 (miRDB score ≥ 95) were considered. 
Treatment 
Group  
















TOC 3 h AIV 15 105 3 11 94 1 4 11 2 
TOC 3 h LPS 3 34 4 3 34 4 0 N/A N/A 
TOC 3 h 
polyI:C 
2 151 14 2 151 14 0 N/A N/A 
TOC 18 h AIV 5 25 17 3 17 2 2 8 15 
TOC 18 h LPS 47 578 14 32 447 10 15 112 4 
TOC 18 h 
polyI:C 
42 384 17 2 146 13 40 233 5 
EV AIV 78 487 16 21 119 9 57 346 9 
EV LPS 22 147 11 5 16 3 17 131 8 
EV polyI:C 104 817 23 14 167 17 90 628 9 
Figure 5. Heat ap with hierarchical clustering of miRNA distribution of the top EV DE miRNAs
ranked by adjusted p-value (FDR). (a) The top 20 DE miRNAs (of 9 that pas the FDR threshold) AIV
group. (b)The top 20 DE miRNAs (of 31 that pas the FDR threshold), LPS group. (c) The top 20 DE
miRNAs (of 147 that pas the FDR threshold) polyI:C group. FDR < 0.05. The density of the colors
represents abundance of each miRNA in the scale of log2 counts per million (CPM).
3.3. Target Gene Prediction and Functional Annotation Reveals DE miRNAs Target Multiple Pathways
The miRDB and TargetScan databases were used to predict the possible gene set or pathway targets
of DE miRNAs to characterize molecular and immunoregulatory functions of DE miRNAs presented in
the current study. Target genes were predicted based on Homo sapiens (human), Mus musculus (mouse),
and Gallus gallus (chicken) targets. However, there was limited information on Gallus gallus targets;
therefore, the results based on the chicken database are provided in the Supplementary Materials
(Tables S5–S9). The results presented in this study are based on human and mice databases. A total
of 105, 34, and 151 projected genes and three, four, and 14 projected pathways were targeted by 15,
three, and two DE cellular miRNAs in 3 h TOC AIV, LPS, and polyI:C groups, respectively. Moreover,
25, 578, and 384 projected genes and 17, 14, and 17 projected pathways were targeted by five, 47,
and 42 DE miRNAs in 18 h TOC AIV, LPS, and polyI:C treatment groups, respectively (Tables 5–7).
Finally, a total of 487, 147, and 817 genes and 16, 11, and 23 pathways were identified as targets for 78,
22, and 104 DE EV miRNAs following AIV, LPS, and polyI:C treatments (EV samples), respectively
(Tables 5, 8 and 9). The targeted pathways related to immune responses and intracellular signaling are
illustrated in Figure 6, while a complete list of targeted pathways and the respectively responsible
miRNAs are provided in Tables 6–9.
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Table 5. Pathway analysis summary. Host target genes for DE miRNAs were predicted using the
miRDB human and mouse databases. Pathway analysis was then performed using the gene set
characterization pipeline by KnowEnG. Only hits with scores greater than or equal to 95 (miRDB
score ≥ 95) were considered.
Treatment












TOC 3 h AIV 15 105 3 11 94 1 4 11 2
TOC 3 h LPS 3 34 4 3 34 4 0 N/A N/A
TOC 3 h polyI:C 2 151 14 2 151 14 0 N/A N/A
TOC 18 h AIV 5 25 17 3 17 2 2 8 15
TOC 18 h LPS 47 578 14 32 447 10 15 112 4
TOC 18 h polyI:C 42 384 17 2 146 13 40 233 5
EV AIV 78 487 16 21 119 9 57 346 9
EV LPS 22 147 11 5 16 3 17 131 8
EV polyI:C 104 817 23 14 167 17 90 628 9
Table 6. Prediction of pathways targeted by up-regulated cellular DE miRNAs following treatment
with AIV, LPS, and polyI:C. Pathways predicted for up-regulated cellular DE miRNAs collected 3 h
and 18 h post-stimulation following treatment with AIV, LPS, and polyI:C using the miRDB human
and mouse database.
Treatment Group Pathway miRNA(s)
TOC 3 h
TOC 3 h AIV mRNA processing gga-let-7c-5p, gga-let-7l-5p,gga-miR-129-5p
TOC 3 h LPS





Splicing factor NOVA regulated
synaptic proteins gga-miR-1608
Synaptic vesicle pathway gga-miR-6704-5p
TOC 3 h polyI:C
Imatinib resistance in
chronic myeloid leukemia gga-miR-12235-5p
PluriNetWork gga-miR-12235-5p
Calcium regulation in the cardiac cell gga-miR-12235-5p
SIDS susceptibility pathways gga-miR-12235-5p
Gastric cancer network 1 gga-miR-12235-5p
Stabilization and expansion
of the E-cadherin adherens junction gga-miR-12235-5p
Fanconi anemia pathway gga-miR-12235-5p





Glial cell differentiation gga-miR-12235-5p
Validated nuclear estrogen
receptor alpha network gga-miR-12235-5p
Visual signal transduction: cones gga-miR-12235-5p
Integrin-mediated cell adhesion gga-miR-12235-5p
Synaptic vesicle pathway gga-miR-12235-5p
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Table 6. Cont.
Treatment Group Pathway miRNA(s)
TOC 18 h
TOC 18 h AIV
Regulation of Toll-like
receptor signaling pathway gga-miR-12244-5p
Notch signaling pathway gga-miR-12244-5p







EGF/EGFR signaling pathway gga-miR-145-5p






Regulation of nuclear beta catenin
signaling and target gene
transcription
gga-miR-145-5p
Regulation of RAC1 activity gga-miR-205a




















TOC 18 h polyI:C
Imatinib resistance in chronic myeloid
leukemia gga-miR-12235-5p
PluriNetWork gga-miR-12235-5p
Calcium regulation in the cardiac cell gga-miR-12235-5p
SIDS susceptibility pathways gga-miR-12235-5p
Gastric cancer network 1 gga-miR-12235-5p
Stabilization and expansion of the
E-cadherin adherens junction gga-miR-12235-5p
Fanconi anemia pathway gga-miR-12235-5p





Glial cell differentiation gga-miR-12235-5p
Validated nuclear estrogen
receptor alpha network gga-miR-12235-5p
Visual signal transduction: cones gga-miR-12235-5p
Synaptic vesicle pathway gga-miR-12235-5p
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Table 7. Prediction of pathways targeted by down-regulated cellular DE miRNAs following treatment
with AIV, LPS and polyI:C. Pathways predicted for down-regulated cellular DE miRNAs collected 3 h
and 18 h post-stimulation following treatment with AIV, LPS, and polyI:C using the miRDB human
and mouse database.
Treatment Group Pathway miRNA(s)
TOC 3 h
TOC 3 h AIV
Ectoderm differentiation gga-miR-6611-5p
Validated targets of C-MYC transcriptional
activation gga-miR-383-5p
TOC 3 h LPS N/A N/A
TOC 3 h polyI:C N/A N/A
TOC 18 h
TOC 18 h AIV
Insulin Signaling gga-miR-1793
EGF/EGFR signaling pathway gga-miR-1793
ErbB1 downstream signaling gga-miR-1793
EGFR1 signaling pathway gga-miR-1793
TNF-alpha NF-kB signaling pathway gga-miR-1793
p38 MAPK signaling pathway gga-miR-1793
MAPK signaling pathway gga-miR-1793
Trk receptor signaling mediated
by the MAPK pathway gga-miR-1793
Signaling mediated by p38-alpha and p38-beta gga-miR-1793
Serotonin receptor 4/6/7 and NR3C signaling gga-miR-1793
Structural pathway of interleukin 1 (IL-1) gga-miR-1793
LPA4-mediated signaling events gga-miR-1793
Interferon type I signaling pathways gga-miR-1793
Bladder cancer gga-miR-1793
BDNF signaling pathway gga-miR-1793
TOC 18 h LPS
Circadian rhythm related genes gga-miR-12239-3p,gga-miR-124a-5p
p53 signaling gga-miR-124a-5p, gga-miR-1783
PluriNetWork gga-miR-124a-5p
TNF-alpha NF-kB signaling pathway gga-miR-7457-5p
TOC 18 h polyI:C
Ectoderm differentiation gga-miR-1c, gga-miR-6611-5p,gga-miR-6706-5p







TNF-alpha NF-kB signaling pathway gga-miR-6641-5p,gga-miR-7480-5p
Table 8. Prediction of pathways targeted by up-regulated EV DE miRNAs following treatment
with AIV, LPS and polyI:C. Pathways predicted for up-regulated EV DE miRNAs collected 3 h and
18 h post-stimulation following treatment with AIV, LPS, and polyI:C using the miRDB human and
mouse database.
Treatment Group Pathway miRNA(s)
EV AIV
FOXA1 transcription factor network gga-miR-15b-5p
GPCRs, Class A Rhodopsin-like gga-miR-6616-5p
Insulin signaling gga-miR-1563, gga-miR-15b-5p
mir-124 predicted interactions with cell cycle and
differentiation gga-miR-92-5p
mRNA processing gga-miR-15b-5p, gga-miR-1452,gga-miR-6543-5p
p73 transcription factor network gga-miR-194
TGF-beta signaling pathway gga-miR-15b-5p
Validated targets of C-MYC transcriptional activation gga-miR-383-5p
Validated targets of C-MYC transcriptional repression gga-miR-6708-5p
Vaccines 2020, 8, 438 20 of 31
Table 8. Cont.




Validated targets of C-MYC transcriptional activation gga-miR-383-5p
EV polyI:C
Calcium regulation in the cardiac cell gga-miR-12235-5p
Fanconi anemia pathway gga-miR-12235-5p
Focal adhesion-PI3K-Akt-mTOR-signaling pathway gga-miR-12235-5p
Gastric cancer network 1 gga-miR-12235-5p
Glial cell differentiation gga-miR-12235-5p
Imatinib resistance in chronic myeloid leukemia gga-miR-12235-5p
PluriNetWork gga-miR-12235-5p
SIDS Susceptibility pathways gga-miR-12235-5p
Splicing factor NOVA regulated synaptic proteins gga-miR-1608
Stabilization and expansion of the E-cadherin adherens
junction gga-miR-12235-5p
Synaptic vesicle pathway gga-miR-12235-5p
Validated nuclear estrogen receptor alpha network gga-miR-12235-5p
Visual signal transduction: cones gga-miR-12235-5p
XPodNet - protein-protein interactions
in the podocyte expanded by STRING gga-miR-1456-5p
Table 9. Prediction of pathways targeted by down-regulated EV DE miRNAs following treatment with
AIV, LPS, and polyI:C. Pathways predicted for down-regulated EV DE miRNAs collected 3 h and 18 h
post-stimulation following treatment with AIV, LPS, and polyI:C while using the miRDB human and
mouse database.
Treatment Group Pathway miRNA(s)
EV AIV
Caspase cascade in apoptosis gga-miR-1784b-5p, gga-miR-3536
Direct p53 effectors gga-miR-12247-3p, gga-miR-12284-3p,gga-miR-205b, gga-miR-142-5p
Imatinib resistance in chronic myeloid
leukemia gga-miR-1724, gga-miR-6639-5p
Regulation of RAC1 activity gga-miR-205b, gga-miR-449b-5p
Splicing factor NOVA regulated synaptic
proteins gga-miR-7456-5p
Synaptic vesicle pathway gga-miR-1632-5p, gga-miR-3532-5p,gga-miR-6639-5p
TGF-beta signaling pathway gga-miR-1632-5p, gga-miR-142-5p,gga-miR-1727
Validated targets of C-MYC transcriptional
repression gga-miR-12247-3p, gga-miR-1626-5p
XPodNet - protein-protein interactions





Caspase Cascade in apoptosis gga-miR-1784b-5p
Direct p53 effectors gga-miR-12284-3p, gga-miR-205b
Globo sphingolipid metabolism gga-miR-1597-5p, gga-miR-211
PluriNetWork gga-miR-449b-5p
PodNet: protein-protein interactions in the
podocyte gga-miR-107-5p, gga-miR-205b
Regulation of RAC1 activity gga-miR-205b, gga-miR-449b-5p
Stabilization and expansion of the
E-cadherin adherens junction gga-miR-211
XPodNet - protein-protein interactions in
the podocyte expanded by STRING
gga-miR-107-5p, gga-miR-205b,
gga-miR-211
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Table 9. Cont.
Treatment Group Pathway miRNA(s)
EV polyI:C
BMP receptor signaling gga-miR-1677-5p, gga-miR-490-5p,gga-miR-7454-3p






























XPodNet – protein-protein interactions








Our data demonstrated that DE miRNAs may target several genes and pathways that play roles
in cell physiology, cell cycle, and immune responses. Based on the target pathway predictions
obtained for the TOC 3 h groups, some miRNA may regulate several pathways, such as the
brain-derived neurotrophic factor (BDNF) and PI3K-Akt-mTOR-signaling pathways. In addition,
the PI3K-Akt-mTOR-signaling pathway was predicted for target genes of both the up-regulated TOC
3 h LPS and up-regulated TOC 3 h polyI:C groups, and they could be regulated by different miRNAs,
such as gga-miR-6704-5p and gga-miR-12235-5p, respectively (Figure 6a, Table 6).
For TOC 18 h groups, the TNF-alpha NF-κB signaling pathway was found to be targeted by
gga-miR-1793, gga-miR-7457-5p (AIV group), and gga-miR-6641-5p (LPS group) and gga-miR-7480-5p
(polyI:C group). Finally, for the TOC 18 h AIV treatment group, the regulation of TLR signaling
pathway was found to be targeted by gga-miR-12244-5p, which was DE following AIV infection
(Figure 6b,c, Tables 6 and 7).
The results presented here demonstrated that EV up-regulated miRNAs following AIV infection
potentially could target gene sets related to mRNA processing and c-myc, while other gene sets or
pathways could be targeted by EV down-regulated miRNA following AIV infection, such as the
TGF-beta pathway and caspase cascade in apoptosis. Some gene sets, such as c-myc or TGF-beta
signaling related genes related genes, can be regulated by both up-regulated or down-regulated EV
miRNAs following AIV infection.
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Our results demonstrated that certain pathways were uniquely targeted by DE miRNAs in a
specific treatment group. For example, it was predicted that the p73 transcription factor network may
be targeted by up-regulated miRNAs following AIV infection in EV samples. Our results predicted that
the caspase cascade during the apoptosis process can be regulated by gga-miR-1784b-5p, which was
down-regulated in both the EV LPS and EV polyI:C groups. DE EV miRNAs following polyI:C treatment,
such as gga-miR-12235-5p, gga-miR-1632-5p, gga-miR-218-5p, and gga-miR-7482-5p, are potentially
able to regulate circadian rhythm related genes, direct p53 effectors and PI3K-Akt-mTOR-signaling
pathway (Figure 6d,e, Tables 8 and 9).
It was projected that some DE miRNAs, such as gga-miR-449b-5p or gga-miR-205b may target
several pathways. For example, gga-miRNA-205b can potentially regulate mRNA processing, p53
transcription factor and Ras-related C3 botulinum toxin substrate 1 (RAC1) pathway (Table 9).
Furthermore, gga-miR-12284-3p was also a miRNA down-regulated in all EV groups. Our data from
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the target gene set prediction within all three different treatments showed that this miRNA could
regulate p53 transcription factor (Table 9). The gga-miR-383-5p, which was down-regulated in the
TOC 3 h treatment group, was predicted to target and potentially regulate the c-myc pathway (Table 8).
In addition, this miRNA was up-regulated following infection with AIV and stimulation with LPS in
the EV treatment groups and it may also target the c-myc pathway based on the EV data (Table 9).
3.4. The Functional Annotation Reveals DE miRNAs Target Multiple Segments of the AIV Viral Genome
We also investigated the target of miRNAs within the AIV viral genome in order to determine the
possible roles of DE miRNAs in AIV infection. A total of 26 miRNAs were determined to target at least
one segment of the viral genome (Table 10). One miRNA, gga-miR-1784b-5p, was found to potentially
target two viral segments, segment 5 (NP protein) and segment 7 (M1 protein). Figure 7 illustrates
the target sites within the viral segments. Our results demonstrated that some down-regulated EV
miRNAs such as gga-miR-107-5p, gga-miR-6665-5p and gga-miR-1784b-5p, possibly can target AIV
segments (Table 10). Among the DE miRNAs targeting the AIV viral genome in both the TOC and EV
treatment groups, 4 miRNAs were up-regulated, and 22 miRNAs were down-regulated. In addition,
the secondary structures for the miRNA-RNA interactions were predicted using RNAhybrid, which
was also used to predict and confirm the mfe values predicted by miRanda (Figure S6).
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Table 10. MiRNAs targeting the viral genome. Viral target sites for DE miRNAs were predicted using
the miRanda and RNAhybrid algorithms. MiRNAs targeting specific segments are indicated, along
with targets positions, miRanda scores, free energy and expression (up- or down-regulation) within the
treatment groups.






gga-miR-122b-3p 1207–1227 170 −17.54 Downregulated in EV AIV
gga-miR-146a-5p 1896–1917 161 −17.51 Upregulated in TOC LPS 18 h
gga-miR-146b-5p 1896–1917 161 −17.87 Upregulated in TOC LPS 18 h
gga-miR-1720-5p 1249–1268 177 −32.16 Downregulated in TOCpolyI:C 18 h
gga-miR-6671-5p 578–601 161 −22.53 Downregulated in EV AIV &EV polyI:C
Segment 2 PB1,
PB1-F2
gga-miR-107-5p 774–796 163 −20.95 Downregulated in EV AIV,EV LPS & EV polyI:C
gga-miR-12223-3p 1328–1349 160 −27.23 Downregulated in EV LPS &EV polyI:C
gga-miR-129-5p 2264–2284 179 −24.92 Upregulated in TOC AIV 3h
gga-miR-132b-5p 91–111 160 −20.56 Downregulated in EV LPS &EV polyI:C
gga-miR-1661 1822–1844 163 −26.29 Downregulated in EV AIV
gga-miR-6641-5p 1729–1750 176 −16.88 Downregulated in TOCpolyI:C 18 h
Segment 3 PA
gga-miR-1573 1027–1047 166 −19.85 Downregulated in EV polyI:C
gga-miR-1663-5p 266–285 162 −26.14 Downregulated in EV polyI:C
gga-miR-1715-5p 1439–1463 161 −24.17 Downregulated in EV AIV &EV polyI:C
gga-miR-6665-5p 2005–2025 162 −20.58 Downregulated in EV AIV,EV LPS & EV polyI:C
gga-miR-7454-3p 944–968 160 −19.88 Downregulated in EV AIV &EV polyI:C
Segment 4 HA
gga-miR-1593 500–520 161 −21.16 Downregulated in TOCpolyI:C 18 h
gga-miR-1605 55–76 168 −20.89 Downregulated in EV AIV &EV polyI:C
gga-miR-1671 761–783 161 −24.1 Downregulated in TOCpolyI:C 18 h
Segment 5 NP
gga-miR-12269-3p 67–88 160 −22.67 Downregulated in EV AIV &EV polyI:C
gga-miR-145-5p 291–313 167 −22.82 Upregulated in TOC LPS 18 h
gga-miR-1784b-5p 1163–1186 163 −21.01 Downregulated in EV AIV,EV LPS & EV polyI:C
gga-miR-6679-5p 786–809 178 −20.29 Downregulated in EV polyI:C
Segment 6 NA
gga-miR-1783 455–477 163 −20.22 Downregulated in TOC LPS18 h
gga-miR-218-5p 535–553 160 −23.78 Downregulated in EV AIV &EV polyI:C
Segment 7 M1, M2 gga-miR-1710 569–590 164 −19.87 Downregulated in EV AIV
gga-miR-1784b-5p 565–588 161 −18.81 Downregulated in EV AIV,EV LPS & EV polyI:C
Segment 8 NS1, NEP NONE N/A N/A N/A N/A
4. Discussion
Studies investigating cellular miRNAs following viral infections are essential for providing insight
into the role of miRNAs in intracellular communication and the induction of antiviral responses.
Identifying the mechanisms that can be regulated by miRNAs following infections or treatments will
expand the current knowledge of host-pathogen interactions. This regulation is complex and, while
host miRNAs can positively regulate antiviral responses, viruses have also been shown to impact
miRNA expression to favor viral infection [66]. Here, we report for the first time that chicken tracheal
cells secrete EVs. This work revealed that EV miRNAs have the potential to regulate antiviral responses
in chickens. Furthermore, we observed that the miRNA profiles of chicken tracheal cells depend on the
source (cellular versus EV) and the treatment (AIV, LPS, or polyI:C). These differences in the profile of
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miRNAs can be associated with active machinery of cargo loading during EV maturation and release.
Previous studies have demonstrated that multiple mechanisms, including the endosomal sorting
complex required for transport (ESCRT)-dependent and ESCRT-independent pathways, regulate the
content of the EVs [67,68]. In addition, viral infections or stimulation via TLRs can change the EV
cargo composition by targeting these pathways [8].
Additionally, we found a group of miRNAs that are in common among the different treatment
groups in EV samples, while they are significantly affected by treatments. This suggests that, while the
treatment groups have distinct miRNA expression profiles, certain miRNAs may have a fundamental
role in which their loading into the EVs is independent of treatment or independent of the active cargo
loading process.
EVs and their contents, including miRNAs, play critical roles in the regulation of the immune
responses in the recipient cells by either activating or suppressing immune response genes [69,70].
In the context of influenza virus infections, previous studies demonstrated that miRNAs regulate
antiviral responses by suppressing intracellular signaling pathways or activating pathways downstream
of pattern recognition receptors (PRRs). For example, miR-92-5p, which was up-regulated in EVs
following AIV infection, is able to enhance the activity of the NF-κB pathway [71]. Meanwhile, the
expression of miR-449b-5p was suppressed following virus infection. The miR-449 family mainly
interfere with influenza virus infection by enhancing type I IFNs [18]. Therefore, as highlighted in
this study, the type of stimuli affected the EV cargo and, subsequently, can have potential impact
on the recipient cells. It is likely to expect that the treatment of host cells with specific miRNAs in
EVs that activate antiviral responses in the recipient cells may limit the replication of the virus in the
neighboring cells. On the other hand, the virus may down-regulate the expression of some EV miRNAs
and interfere with antiviral responses.
Network-guided gene set characterization analysis using KnowEnG’s analytical platform enabled
the identification of important GO terms and pathways, while incorporating co-expression relationships
among targets of DE miRNAs [53]. These pathway analyses demonstrated that DE EV miRNAs can
target several pathways that are critical during influenza virus infection, such as RAC1 and TGF-beta
signaling pathways. The RAC1 pathway has been shown to enhance the replication of the influenza
virus [72]. Therefore, targeting this pathway, through specific miRNAs, such as miR-205a, can be a
strategy to limit the replication of the influenza virus either in the target cells or neighboring cells
through EVs.
Analysis of the miRNA profile in chicken tracheal cells at different time points showed that the
type of stimuli impacts the profile of DE miRNAs. For instance, the majority of the differentially
expressed miRNAs were down-regulated in the polyI:C treatment group, while the majority of the
differentially expressed miRNAs were up-regulated in AIV infection group at an early time point.
Previous studies in chickens highlighted the possible role of miRNAs in the regulation of immune
responses and the modulation of Marek’s disease virus or avian influenza virus. As highlighted in
the study by Wang et al., the profile of expressed miRNAs or miRNA-related mechanisms that are
involved in the regulation host immune response could vary depending on the type of virus, cell
stimuli, and the time point [33,73].
Moreover, as previously suggested, our analyses showed that multiple miRNAs can target the
same gene and that, equally, a single miRNA can have multiple gene targets [74]. This suggests that it is
potentially a combination of miRNA activities that modulate target gene expression. Among the cellular
TOC samples, the distinct miRNA expression characteristics at different post-infection or -stimulation
time points (3 h and 18 h) suggests that the expression of certain miRNAs is time-dependent. There
were not any common DE miRNAs within each treatment group among different time points.
While the functions of most of the DE miRNAs identified in the various treatment groups remain
unknown, some have been reported to be involved in the regulation of host immune responses and
host-pathogen interactions. Previously, we showed that, in the same tissues, LPS is a potent TLR ligand
for inducing pro-inflammatory cytokines, such as IL-6 and IL-1β cells, which limit the replication of
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AIV [1,2,36]. The current study showed that LPS up-regulated the expression of miR-146a in tracheal
cells at a later time point. A previous study demonstrated that the activation of NF-κB signaling pathway
leads to the up-regulation of miR-146a, which regulates and controls pro-inflammatory responses [75].
Moreover, miR-181 family, including miR-181a and -b, regulates pro-inflammatory responses by
regulating NF-κB signaling pathway [76–78]. In this study, the expression of both miRNA-181a
and -b was increased following LPS treatment. This result is in alignment with previous reports
indicating increased expression of miR181b following LPS treatment in chicken macrophages [79].
Therefore, expressed miRNAs, such as miR-181 family or 146a following LPS treatment, can control
pro-inflammatory responses through the NF-κB signaling pathway.
In addition, the results of the current study demonstrated that some miRNAs have the potential
to target both innate and adaptive immune responses. For example, some DE miRNAs, such as
gga-miR-205b and gga-miR-124a-5p, target p53 signaling pathway (Figure 6c,e, Tables 7,9). It has
been demonstrated that p53 serves as a host antiviral factor by enhancing cytokine and antiviral gene
responses in the lung, increasing the activity of dendritic cells (DC) and influenza-specific CD8+ T
cells [80]. Therefore, these miRNAs could be employed to develop anti-influenza strategies and vaccine
adjuvants for the control of AIV in chickens.
In addition, previous studies have also implied that miR-146 is involved in the regulation of
immune responses to Salmonella infection in mice and it has direct targets within TLR signaling [81–83].
Our results indicated that gga-miR-12244-5p may target TLR signaling pathways. The miRNA
gga-miR-146b-5p was previously suggested to be involved in the general process of inflammation
during Avian pathogenic Escherichia coli (APEC) infection in chickens [28].
The DE miRNAs play a role in the regulation of antiviral responses, but they also might target
the AIV genome. We were interested in miRNA target sites in the AIV genome, as recent studies
have indicated that miRNAs may be capable of regulating virus translation and replication by directly
binding to the virus genome [22–27]. While investigating the potential targets in the AIV viral genome,
we determined that seven out of eight segments were targeted by at least one miRNA, suggesting
that it is possibly a combination or cooperation of miRNA activity that can control viral activity.
Our results demonstrated that both gga-miR-146a-5p and gga-miR-146b-5p, which are part of the
same gene family, target segment 1 (PB2 protein) of the AIV genome. This suggests that, while
gga-miR-146a-5p and gga-miR-146b-5p may play a role in modulating TLR signaling, they potentially
have a dual function in regulating the PB1 protein. In addition, gga-miR-1784b-5p was the only miRNA
identified that targeted more than one viral segment of AIV, both segment 5 (NP protein) and segment
7 (M1 protein). Our results suggest that this miRNA has multiple targets, both in the host and viral
genomes. Several other miRNAs, gga-miR-129-5p, gga-miR-6641-5p, and gga-miR-1663-5p, target host
mRNA processing and NF-kB signaling pathways, while also potentially targeting segments 2 (PB1
protein) and 3 (PA protein) of AIV.
5. Conclusions
In summary, we investigated the global miRNA expression profile in chicken tracheas in response
to AIV infection and TLR ligand stimulation and the potential roles of specific DE miRNAs. Our results
highlighted the possible role of EV contents in regulating antiviral responses. This accumulated
evidence presented here elucidated the potential function of the candidate miRNAs on the host
responses to AIV infection. We inferred that miRNAs play a major role in AIV infection and they can
coordinate host defense against viral infections. In this study, the miRNA expression profiles were
significantly regulated by the treatments with AIV, LPS, and polyI:C. These DE miRNAs were found to
potentially target both host and viral genes. This study identified several miRNAs, such as miR-146a,
miR-146b, miR-205a, miR205b, and miR-449, which could be employed in alternative strategies for
the control of AIV in chickens, such as miRNA-based antiviral agents or vaccine adjuvants. Further
functional studies are required to confirm the effect of treatment with candidate miRNA to inhibit AIV
infection and induce stronger immune responses in in vitro and in vivo models.
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